iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Consensus Price Target from Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have earned an average recommendation of “Buy” from the five research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $120.00.

IRMD has been the subject of a number of recent analyst reports. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Lake Street Capital restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings upgraded shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday. Finally, Roth Mkm restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th.

Insiders Place Their Bets

In related news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $101.38, for a total value of $506,900.00. Following the completion of the transaction, the chief executive officer directly owned 2,242,500 shares in the company, valued at $227,344,650. The trade was a 0.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 52,500 shares of company stock valued at $5,030,288. 36.80% of the stock is owned by insiders.

Hedge Funds Weigh In On iRadimed

Hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its holdings in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the last quarter. CWM LLC grew its position in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the period. Quarry LP bought a new stake in iRadimed in the 3rd quarter worth approximately $40,000. State of Alaska Department of Revenue bought a new stake in iRadimed in the 3rd quarter worth approximately $47,000. Finally, Tower Research Capital LLC TRC grew its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Stock Performance

IRMD stock opened at $86.29 on Friday. The firm has a 50 day moving average price of $95.79 and a 200-day moving average price of $94.42. iRadimed has a 52-week low of $50.88 and a 52-week high of $107.90. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 47.15 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts forecast that iRadimed will post 1.94 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is presently 43.72%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.